Cynata Therapeutics Limited (AU:CYP) has released an update.
Cynata Therapeutics Limited, an Australian biotech firm, invites shareholders to an investor webinar to discuss advancements in their proprietary stem cell platform, Cymerus™, and various ongoing clinical trials. The webinar, which includes a live Q&A with CEO Dr. Kilian Kelly, aims to update investors on recent successes, including their lead product candidate’s positive results in a Phase 1 trial for treating steroid-resistant acute graft-versus-host disease. Interested parties can register for the event online and access the updated investor presentation attached to the company’s announcement.
For further insights into AU:CYP stock, check out TipRanks’ Stock Analysis page.
